Consuela A. Albright: The Strategic Value of Proclamations in Health Advocacy
Consuela A. Albright, Nurse Practitioner at Cleveland Clinic, shared a post on LinkedIn:
“Quick advocacy lesson: you’ve probably seen ‘the mayor issued a proclamation for Sickle Cell Awareness Month’ – but what does that actually accomplish?
A proclamation is a formal, public statement from an elected official (a mayor, governor, or even the President) recognizing a cause.
On its own, it doesn’t include funding or legal force.
So why do advocacy organizations spend real time and energy securing them every year?
Because a proclamation is a lever, not an outcome. It:
- Creates a public record that an elected official acknowledged the issue – useful the next time advocates ask that official for policy action or funding.
- Generates local media coverage, which raises visibility for events, screenings, and fundraising.
- Signals to community organizations that they have a friend in that office, which can open doors for future partnerships.
- Gives advocates a concrete, achievable ‘win’ that builds momentum toward harder asks.
It’s a small ask that opens the door to bigger ones.
That’s advocacy strategy in miniature – and it’s exactly what national organizations coordinate every September.”
Stay updated with Hemostasis Today.
-
Sep 12, 2026, 17:55Dries De Wolf: Honored to Have Wolfgang Miesbach Comment on Our Latest Research
-
Sep 12, 2026, 17:53Usman Waheed: Introducing the Discovery of the 49th ISBT Blood Group System
-
Sep 12, 2026, 17:51Maria Sabater Lleal: Happy to Share Our Latest Work Exploring the Genetic Determinants of PE in VTE
-
Sep 12, 2026, 17:51Jeff Sternlicht: Why LDL-C and ApoB Remain King of the Hill?
-
Sep 12, 2026, 17:49Kalyan Roy: TRAGS – An Emerging Transfusion Safety Concern
-
Sep 12, 2026, 17:48Jason Fung: What Happened to “Statins Save Lives”?
-
Sep 12, 2026, 17:47Eric Topol: Most Supplements and Vitamins Offer Little Proven Benefit
-
Sep 12, 2026, 17:44Manuel Monreal: Clinical Characteristics, Treatment, and Outcomes in Hispanic vs Caucasian Patients With VTE
-
Sep 12, 2026, 17:43Sidi Mohamed El Amine Benlazar: CPX-351 and Ruxolitinib in Advanced-Phase Myeloproliferative Neoplasms